A phase II trial evaluated the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib in 178 tumor patients with V600E mutations, involving 33 patients with terminal CCA (31). Here, MAP2K7 is linked to cholangiocarcinoma.